BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

PHASE2UnknownINTERVENTIONAL
Timeline

Start Date

November 30, 2000

Conditions
Lung Cancer
Interventions
DRUG

BBR 3464

Trial Locations (18)

22908

Cancer Center at the University of Virginia, Charlottesville

35216

Clinical Research Consultants, Inc, Hoover

43214

Cancer Services, Columbus

46202

Indiana Cancer Pavilion, Indianapolis

46617

Michiana Hematology/Oncology P.C., South Bend

63110

Washington University Barnard Cancer Center, St Louis

70506

Louisiana Oncology Associates, Lafayette

72703

Highlands Oncology Group, P.A., Fayetteville

74104

Oklahoma Oncology Inc., Tulsa

94704

Alta Bates Comprehensive Cancer Center, Berkeley

06489

Office of Peter D. Byeff, Southington

60611-3013

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

40536-0084

University Hospital Lexington, Lexington

02215

Beth Israel Deaconess Medical Center, Boston

08543

Theradex, Princeton

27599-7295

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

19104-4283

University of Pennsylvania Cancer Center, Philadelphia

23298-0037

Massey Cancer Center, Richmond

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theradex

INDUSTRY

NCT00014547 - BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment | Biotech Hunter | Biotech Hunter